ArticleJournal of hematopathology2026
Immunophenotypic aberrancies in molecularly confirmed acute promyelocytic leukemia: lessons from two cases.
Article in Journal of hematopathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia characterized by PML::RARA fusion, typical morphology, and a characteristic flow cytometric immunophenotype that enables rapid diagnosis. However, immunophenotypic aberrancies may occur and can mimic mixed phenotype acute leukemia (MPAL), leading to diagnostic and therapeutic dilemmas. We report two adult male patients with APL confirmed by fluorescence in situ hybridization (FISH) demonstrating PML::RARA fusion. Both cases exhibited unusual immunophenotype. In the first case, peripheral blood flow cytometry revealed blasts with bright cMPO, CD34, dim HLA-DR, along with aberrant expression of CD19 (moderate), cCD79a (dim), cCD3 (heterogeneous), and CD7, raising a suspicion for MPAL. However, lineage defining criteria for T- and B-lineages were not fulfilled. Marrow showed abnormal promyelocytes with bundles of Auer rods, and molecular studies confirmed APL. In the second case, morphology suggested microgranular variant APL. Flow cytometry demonstrated aberrant expression of lymphoid and monocytic markers, including CD19 (dim), sCD3 (moderate), CD7, and CD14 (moderate), in addition to cMPO. Cytogenetics and molecular studies confirmed t(15;17)/PML::RARA in both cases, along with FLT3-ITD mutations. One patient developed differentiation syndrome and responded to all-trans-retinoic acid, while the follow-up of the second patient is unavailable. APL may exhibit immunophenotypic aberrancies mimicking MPAL. Molecular confirmation of PML::RARA and an integrated diagnostic approach are essential to avoid misclassification and ensure timely therapy.
Indexed as
Identifiers
42133174What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.